Brigatinib versus other second-generation ALK inhibitors as initial treatment of anaplastic lymphoma kinase positive non-small cell lung cancer with deep phenotyping: study protocol of the ABP trial.
Petros ChristopoulosFarastuk BozorgmehrLena BrücknerInn ChungJohannes KrisamMarc A SchneiderAlbrecht StenzingerRegina EickhoffDaniel W MuellerMichael ThomasPublished in: BMC cancer (2021)
Clinicaltrials.gov , NCT04318938. Registered March 182,020, https://www.clinicaltrials.gov/ct2/show/NCT04318938 Eudra-CT, 2019-001828-36. Registered September 302,019, https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001828-36.
Keyphrases
- study protocol
- image quality
- dual energy
- computed tomography
- contrast enhanced
- randomized controlled trial
- clinical trial
- positron emission tomography
- high throughput
- diffuse large b cell lymphoma
- open label
- phase iii
- magnetic resonance imaging
- phase ii
- advanced non small cell lung cancer
- tyrosine kinase
- protein kinase
- smoking cessation